Compare · GNLX vs NVO
GNLX vs NVO
Side-by-side comparison of Genelux Corporation (GNLX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GNLX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 1750.8x GNLX ($123.1M).
- Over the past year, GNLX is down 28.4% and NVO is down 12.1% - NVO leads by 16.3 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for GNLX).
- NVO has more recent analyst coverage (25 ratings vs 6 for GNLX).
- Company
- Genelux Corporation
- Novo Nordisk A/S
- Price
- $2.71-0.37%
- $48.65+3.65%
- Market cap
- $123.1M
- $215.46B
- 1M return
- -7.34%
- -2.08%
- 1Y return
- -28.36%
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 5
- 9
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GNLX
- Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Genelux Corporation
- Chief Technical Officer Cappello Joseph sold $1,924 worth of shares (653 units at $2.95), decreasing direct ownership by 0.20% to 328,737 units (SEC Form 4)
- President and CEO Zindrick Thomas sold $8,905 worth of shares (3,023 units at $2.95), decreasing direct ownership by 0.24% to 1,260,890 units (SEC Form 4)
- Chief Scientific Officer Yu Yong sold $1,922 worth of shares (653 units at $2.94), decreasing direct ownership by 0.24% to 268,371 units (SEC Form 4)
- Attovia Therapeutics Appoints John W. Smither to Board of Directors
- Director Smither John W sold $34,898 worth of shares (12,000 units at $2.91), decreasing direct ownership by 12% to 91,403 units (SEC Form 4)
- Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
- SEC Form 8-K filed by Genelux Corporation
- President and CEO Zindrick Thomas was granted 730,601 shares, increasing direct ownership by 137% to 1,263,913 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S